Complete Story
 

02/26/2018

Targrisso

 

Product Website: www.targrissohcp.com

Production Information: For patients with metastatic EGFR T790 mutation positive NSCLC as detected by an FDA approved test, a progression on or after TKI therapy. 

NDC Code: 00310-1350-30   80 mg  30 count

Companion Diagnostic: YES   

REMs: NO 

 

Limited Distribution: YES  

Manufacturer Reimbursement Assistance:

Patient Assistance (844) 275-2360 or www.myaccess360.com.  If there are financial barriers to fulfilling this prescription, www.astrazeneca-us.com/medicines/Affordability.html may be able to help.

Online Information:

 

Direct to patient nurse/clinical support program:

 

Additional products/supplies for patients:

Professional educational materials available from your sales specialist:

Online Information:

The best source of updated product information is your pharmaceutical sales specialist.

To identify or connect with your specialist please contact:

Brian Jenkins

brian.jenkins@astrazeneca.com

614-596-1298

Printer-Friendly Version